Adicet Bio, Inc. is advancing an allogeneic gamma delta (γδ) CAR T-cell platform designed to address unmet needs in autoimmune disorders and solid tumors. Founded in 2014, the Redwood City–based clinical-stage biotechnology company is focused on developing off-the-shelf cell therapies designed to deliver durable immune responses with favorable safety profiles
The platform is built around CAR-engineered γδ T cells, which bridge innate and adaptive immunity. Through the use of gene-editing technologies, Adicet aims to enhance cell potency, persistence, and safety, positioning its therapies as potential one-time interventions capable of inducing long-term immune reset rather than ongoing immunosuppression.
Designed for scale, Adicet’s allogeneic manufacturing approach supports broad clinical application across multiple indications. The platform forms the backbone of the company’s growing clinical pipeline in autoimmune disease and oncology, as its programs continue to progress through early-stage clinical trials.
Strategic growth and funding
In October 2019, Adicet raised $80 million in a Series B financing with support from OrbiMed Advisors, aMoon2 Fund, Novartis Venture Fund, Regeneron, and Johnson & Johnson Innovation. Adicet Bio also completed an underwritten registered direct offering in October 2025, raising approximately $80 million in gross proceeds. The funding extends the company’s cash runway into the second half of 2027, providing financial stability to support ongoing operations and clinical development. Specifically, OrbiMed and affiliated entities bought 5 million shares of Adicet Bio.
The capital will be primarily allocated to advancing Adicet’s autoimmune and oncology programs, including continued patient enrollment and trial progression. The funding also supports regulatory engagement and preparations for potential pivotal trial initiation in 2026, positioning the company to accelerate its clinical and strategic milestones.
Featured patents
The following patents showcase advances in targeted cancer diagnostics and immunotherapy, addressing long-standing challenges in precision, scalability, and treatment durability. Each invention reflects a focused effort to improve how cancers are detected, monitored, and treated by combining biological insight with engineered therapeutic and diagnostic approaches.
AI-enabled detection of membrane-bound GPC3 for cancer diagnosis and therapy
A major limitation in current cancer diagnostics is the inability to reliably distinguish membrane-bound glypican-3 (GPC3) from soluble or degraded forms of the same protein. While GPC3 is a well-recognized biomarker in cancers such as hepatocellular carcinoma, many existing assays lack the specificity needed to confirm whether GPC3 is truly present on the cell surface. This gap can lead to false positives, imprecise patient stratification, and reduced confidence when selecting patients for targeted therapies.
U.S. Pat. App. Pub. No. 2025/0085287 addresses this challenge by introducing methods specifically designed to detect GPC3 when it is present on the surface of cancer cells. The invention uses selective antibodies and testing workflows that focus on the membrane-bound form of GPC3, rather than forms that are circulating freely in the blood or broken down.
This added precision improves the reliability of cancer diagnosis and disease monitoring. By accurately identifying tumors that truly express membrane-bound GPC3, the approach helps clinicians select the patients most likely to benefit from GPC3-targeted therapies, better track treatment response, and reduce uncertainty common with traditional protein detection methods.
The patent, titled “Methods for detection of membrane bound glypican-3,” was filed on August 19, 2022, and published on March 13, 2025. The patent lists Sandra M. Hayes, Jonathan Ta Shin Wong, Arun Bhat, Mustafa Turkoz, Erika Meaddough, Hui Shao, Jacqueline Kennedy Wilde, Ori Maller, Elizabeth Perez, Matthew Ian Hoopes, and Kevin Nishimoto.
Multivalent agents enable controlled expansion of gamma delta T cells for cancer immunotherapy
A persistent challenge in cellular immunotherapy is achieving selective, scalable expansion of specific gamma delta (γδ) T-cell populations without triggering exhaustion, nonspecific activation, or cell death. Conventional stimulation methods often rely on broad activators or feeder systems that lack precision, making it difficult to consistently generate therapeutically relevant γδ T-cell subsets for clinical use.
U.S. Pat. App. Pub. No. 2023/0009275 addresses this problem by introducing methods and compositions that use soluble multivalent activating agents to selectively activate and expand γδ T-cell populations, including defined γδ T-cell subtypes of interest. The invention discloses engineered multivalent constructs, such as IgG-based “scorpion” and mini-scorpion formats, designed to engage target receptors with controlled valency and geometry, enabling potent activation without excessive toxicity or nonspecific signaling.
By tuning the structure and binding properties of these multivalent agents, the disclosed methods support robust in vitro and ex vivo expansion of γδ T cells suitable for therapeutic applications. This approach improves consistency, scalability, and functional quality of expanded cells, supporting their use in treating cancers, infectious diseases, and immune disorders.
The patent, titled “Methods for expanding gamma delta T-Cell populations with multivalent agents and compositions thereof,” was filed on December 3, 2020, and published on January 12, 2023. The patent lists Aya Jakobovits, Daulet Satpayev, Orit Foord, Yifeng Frank Jing, Hui Shao, and Arun Bhat as inventors.
Targeted anti-CD20 CAR T-cell therapy for treating B-cell malignancies
A major challenge in treating B-cell cancers is achieving durable tumor control with manageable toxicity, particularly in patients who relapse after standard therapies. While CAR T-cell therapies targeting CD19 have shown success, resistance, antigen escape, and safety concerns continue to limit long-term effectiveness, creating a need for alternative targets and improved CAR designs.
U.S. Pat. App. Pub. No. 2025/0025504 addresses this problem by disclosing methods and compositions for treating B-cell malignancies using anti-CD20 chimeric antigen receptor (CAR) T cells. The invention describes CAR T-cell designs engineered to specifically target cancer cells that express CD20, along with treatment approaches intended to improve tumor targeting, expansion of CAR T cells in the body, and lasting anti-cancer activity.
These approaches are supported by preclinical and clinical data showing tumor shrinkage, sustained CAR T-cell presence, and measurable patient responses, including complete and partial remissions. By targeting CD20, the methods offer an alternative or complementary option to existing CAR T therapies and may help overcome treatment resistance, expanding options for patients with relapsed or hard-to-treat disease.
The patent, titled “Treatment of B Cell Malignancies,” was filed on June 4, 2024, and published on January 23, 2025. The listed inventors include Blake Aftab, Francesco Galmi, Rose Kamyee Lai, and Ori Maller.
Adicet Bio: Patenting Activity
Adicet Bio, Inc. experienced its most significant patent filing activity in the mid-to-late 2010s, reflecting a concentrated effort to establish its off-the-shelf, allogeneic immune cell therapy platform. Patent filings rose sharply from 2015 through 2018, peaking in 2018. This period coincides with the company’s early formation stage, the acquisition of Applied Immune Technologies, and a 2016 collaboration with Regeneron that included $25 million in upfront funding and multi-year research support focused on engineered CAR and TCR cell therapies.
Following this initial surge, patent activity declined as Adicet transitioned from foundational platform development to clinical execution and capital formation. From 2019 onward, filings became more limited, indicating a shift toward advancing existing intellectual property into the clinic rather than expanding the patent estate at the same pace. This phase aligns with key financing milestones, including an $80 million Series B in 2019 and a $143.8 million combined public and private financing in 2021, which supported the clinical advancement of its gamma delta T-cell programs.
By the mid-2020s, Adicet’s strategy appeared focused on clinical validation and regulatory progress across oncology and autoimmune indications. The reduced filing volume suggests reliance on a mature and established patent portfolio to underpin late-stage development and long-term commercialization efforts, rather than continued broad platform expansion.
Adicet Bio: Top Legal Representatives
Legal representation in Adicet Bio’s global patent and patent application activity between 2015 and 2025 is led by a concentrated group of IP-focused law firms, with Squire Patton Boggs emerging as the most active firm by volume. This is followed closely by Sonoda & Kobayashi, Mathys & Squire, and Gowling WLG, reflecting strong coverage across the United States, Europe, and Japan, which are key jurisdictions for Adicet’s intellectual property strategy.
Additional contributors include Reinhold Cohn and Partners and Spruson & Ferguson, indicating continued emphasis on Israel and the Asia-Pacific region. Other filings are associated with David James Miller as an individual practitioner, alongside firms such as Griffith Hack, Kim & Chang IP, and Washida & Associates, highlighting Adicet Bio’s use of both institutional firms and individual counsel to manage jurisdiction-specific patent prosecutions.
Adicet Bio: Top Technology Trends
Adicet Bio’s global patent activity is strongly concentrated in therapeutic and biologics-focused technologies. The portfolio is primarily anchored in medical and therapeutic preparations classified under A61K and A61P, together with peptide-related innovations under C07K. Collectively, these areas account for the majority of filings and underscore the company’s strategic focus on developing biologic and immune-based cell therapies.
A substantial portion of filings also falls within microorganisms and enzymes under C12N, reflecting core capabilities in cellular engineering, biologic manufacturing, and platform technologies that support therapeutic development. This distribution aligns with Adicet Bio’s emphasis on engineered cell therapies and scalable biologic production systems.
Additional activity in materials analysis and characterization under G01N suggests supporting innovation in testing, validation, and research processes associated with drug development.
Smaller concentrations of filings appear in areas such as refrigeration and preservation systems under F25B, as well as solid-state and semiconductor-related technologies under H01L and H10N.
While limited in volume, these filings likely represent enabling technologies related to storage, processing, instrumentation, or infrastructure used within research and manufacturing environments rather than core therapeutic innovation.
